Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of CS060380 tablets in patients with nonalcoholic steatohepatitis
CTR20253652Phase 2Active
- Sponsor
- Cascade Pharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thybetaxor in metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Cascade Pharmaceuticals. Started Sep 2025; status: active.
02
Drugs
thybetaxor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on CTR20253652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253652.